Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Sitagliptin authorised for renal impairment in diabetes

  • Comment

The drug sitagliptin (Januvia) has been authorised by the Medicines and Healthcare products Regulatory Agency for use in type 2 diabetes patients with moderate to severe renal impairment.

The new indication is based on favourable results from trials involving diabetes patients with moderate to severe renal impairment and diabetes patients with end-stage renal disease on dialysis.

Sitagliptin is manufactured by Merck Sharp & Dohme. It said in patients with moderate to severe renal impairment, a study comparing sitagliptin at 25 or 50mg once daily with glipizide at 2.5-20mg per day showed a mean reduction in HbA1c of 0.76% with sitagliptin and 0.64% with glipizide after 54 weeks.

In patients with ESRD on dialysis, the company said trial results showed treatment with sitagliptin 25mg once daily for 54 weeks provided “clinically meaningful” reductions from baseline in HbA1c (0.72% with sitagliptin versus 0.87% with glipizide).

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.